Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer Patients Undergoing Radical Prostatectomy Clear all
Completed Phase 2 Interventional

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy

NCT00086736
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, eflornithine, oral eflornithine placebo, oral bicalutamide placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Not applicable Interventional

Impact of Yoga As Complementary Therapy in Patients Undergoing Radical Prostatectomy

NCT02620033
View directory record Official record
Conditions
Prostate Cancer
Interventions
Yoga therapy
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jun 26, 2026, 5:37 PM EDT
Recruiting Not applicable Interventional

Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy

NCT04646434
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Electroencephalography, Electromyography, Questionnaire Administration, Urodynamics (UDS)
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy

NCT00003115
View directory record Official record
Conditions
Pain, Prostate Cancer
Interventions
hydromorphone hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

NCT00078910
View directory record Official record
Conditions
Prostate Cancer
Interventions
exisulind, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jun 26, 2026, 5:37 PM EDT
Not listed Not applicable Interventional

ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy

NCT02773940
View directory record Official record
Conditions
Prostate Cancer
Interventions
ClariCore System
Device
Lead sponsor
Precision Biopsy, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 26, 2026, 5:37 PM EDT
Recruiting Phase 2 Interventional

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

NCT06636682
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
Interventions
FK-PC101, Standard of Care (SOC)
Biological
Lead sponsor
Cellvax Therapeutics Inc
Industry
Eligibility
Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jun 26, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

NCT01340599
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 26, 2026, 5:37 PM EDT
Recruiting Phase 1 Interventional

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

NCT06450106
View directory record Official record
Conditions
Prostate Cancer
Interventions
STM-416p
Drug
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Early Phase 1 Interventional

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

NCT07069465
View directory record Official record
Conditions
Prostate Cancer
Interventions
flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone
Diagnostic Test · Drug
Lead sponsor
Urology Clinics of North Texas
Network
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

NCT00321646
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Bevacizumab, Docetaxel
Drug
Lead sponsor
Mary-Ellen Taplin, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

NCT00450749
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene
Other · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jun 26, 2026, 5:37 PM EDT
Completed No phase listed Observational

Men Undergoing Radical Prostatectomy

NCT00582530
View directory record Official record
Conditions
Prostate Cancer
Interventions
Whole Blood Draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

NCT00466752
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
sorafenib tosylate, microarray analysis, immunohistochemistry staining method, gene expression analysis, needle biopsy, therapeutic conventional surgery, laboratory biomarker analysis, western blotting, RNA analysis
Drug · Genetic · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Not applicable Interventional

Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery

NCT01660152
View directory record Official record
Conditions
Male Erectile Disorder, Prostate Cancer, Sexual Dysfunction
Interventions
Sexual Health Inventory for Men (SHIM) questionnaire administration, management of therapy complications, Daily vacuum therapy
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Up to 70 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jun 26, 2026, 5:37 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

NCT06798558
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Lu-17-PSMA-617
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 26, 2026, 5:37 PM EDT
Recruiting Early Phase 1 Interventional

HCQ in Resectable Localized Prostate Cancer

NCT06408298
View directory record Official record
Conditions
Resectable Localized Prostate Cancer
Interventions
Hydroxychloroquine Sulfate 400Mg Tab, Placebo
Drug
Lead sponsor
Lionel.D.Lewis, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 26, 2026, 5:37 PM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer

NCT00052481
View directory record Official record
Conditions
Prostate Cancer
Interventions
quality-of-life assessment
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jun 26, 2026, 5:37 PM EDT
Active, not recruiting Not applicable Interventional

Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy

NCT04299620
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Digital Image Analysis, Radical Prostatectomy, Transrectal Ultrasound
Device · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Not applicable Interventional

Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery

NCT02024178
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ultrasound Imaging
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate

NCT00078923
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy isoflavones, neoadjuvant therapy, Placebo
Dietary Supplement · Procedure · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

NCT00090376
View directory record Official record
Conditions
Impotence, Prostate Cancer
Interventions
GPI 1485
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years to 69 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
25
States / cities
Phoenix, Arizona • La Mesa, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2008 · Synced Jun 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

NCT00071968
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 26, 2026, 5:37 PM EDT
Active, not recruiting Phase 2 Interventional

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

NCT02949284
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Biological · Other + 1 more
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 26, 2026, 5:37 PM EDT